Chromosome 1q21 abnormalities in multiple myeloma
Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …
Gain/amplification of chromosome arm 1q21 in multiple myeloma
I Hanamura - Cancers, 2021 - mdpi.com
Simple Summary Multiple myeloma (MM), a plasma cell neoplasm, is an incurable
hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most …
hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most …
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
The remarkable genetic heterogeneity of multiple myeloma poses a substantial challenge
for proper prognostication and clinical management of patients. Here, we introduce MM …
for proper prognostication and clinical management of patients. Here, we introduce MM …
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
Treatment benefit in multiple myeloma (MM) patients with high‐risk cytogenetics remains
suboptimal. The phase 3 ICARIA‐MM trial (NCT02990338) showed that isatuximab plus …
suboptimal. The phase 3 ICARIA‐MM trial (NCT02990338) showed that isatuximab plus …
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications
E Kastritis, M Migkou, D Dalampira… - American Journal of …, 2022 - Wiley Online Library
Numerical abnormalities of chromosome 1q (+ 1q21) are common in patients with newly
diagnosed multiple myeloma (MM) but their prognostic impact remains a matter of debate. In …
diagnosed multiple myeloma (MM) but their prognostic impact remains a matter of debate. In …
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Background CD38 has been established as an important therapeutic target for multiple
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …
Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma
In multiple myeloma, abnormal plasma cells establish oncogenic niches within the bone
marrow by engaging the NF-κB pathway to nurture their survival while they accumulate pro …
marrow by engaging the NF-κB pathway to nurture their survival while they accumulate pro …
[HTML][HTML] Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
T Martin, PG Richardson, T Facon, P Moreau… - …, 2022 - ncbi.nlm.nih.gov
Gain/amplification of 1q21, referred to as 1q21+ in this letter, is one of the most common
chromosomal abnormalities in multiple myeloma (MM), 1 being detected in approximately …
chromosomal abnormalities in multiple myeloma (MM), 1 being detected in approximately …
[HTML][HTML] Roles of S100 family members in drug resistance in tumors: Status and prospects
X Hua, H Zhang, J Jia, S Chen, Y Sun, X Zhu - Biomedicine & …, 2020 - Elsevier
Chemotherapy and targeted therapy can significantly improve survival rates in cancer, but
multiple drug resistance (MDR) limits the efficacy of these approaches. Understanding the …
multiple drug resistance (MDR) limits the efficacy of these approaches. Understanding the …
Resistance mechanisms towards CD38− directed antibody therapy in multiple myeloma
LE Franssen, CAM Stege, S Zweegman… - Journal of Clinical …, 2020 - mdpi.com
Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple
myeloma (MM). CD38− directed antibodies have several mechanisms of action. Fc …
myeloma (MM). CD38− directed antibodies have several mechanisms of action. Fc …